抗小鼠CD8a单抗(2.43克隆)20篇高分文献汇总与CD8+ T细胞耗竭应用指南

在肿瘤免疫学、传染病机制及自身免疫性疾病的动物模型研究中，验证特定免疫细胞亚群（如细胞毒性 T 淋巴细胞，CTL）的功能是确立作用机制的核心环节。抗小鼠 CD8a 单克隆抗体（克隆号：2.43）是国际学术界广泛认可的用于小鼠体内（In Vivo）特异性清除或耗竭 CD8+ T 细胞的“金标准”试剂。

由 Syd Labs 研发的体内实验级重组抗小鼠 CD8a 单克隆抗体（Rat IgG2b Kappa，货号：PA007167.r2b），通过提取大鼠 2.43 克隆的可变区序列，采用哺乳动物细胞重组表达制备。该抗体具备超低内毒素和高度一致的批次稳定性，在诸多高水平科研课题中发挥了关键作用。

一、 抗小鼠 CD8a 单克隆抗体（克隆号 2.43）20 篇代表性学术文献

以下整理了近年来研究团队使用 2.43 克隆抗小鼠 CD8a 单抗在 PD-1/PD-L1 联合治疗、NK 细胞疗法、STING 激动剂及病毒清除等领域发表的 20 篇 PMC 权威期刊文献：

1. CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models
2. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice
3. Antipodoplanin antibody enhances the antitumor effects of CTLA‐4 blockade against malignant mesothelioma by natural killer cells
4. OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
5. Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases
6. Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy
7. A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies
8. Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis
9. A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8+ T cells
10. Sensory nerves impede the formation of tertiary lymphoid structures and development of protective anti-melanoma immune responses
11. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
12. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
13. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory
14. Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment
15. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity
16. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion
17. Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma
18. Mice with FVB-derived sequence on chromosome 17 succumb to disseminated virus infection due to aberrant NK cell and T cell responses
19. A Sulfur Containing Melanogenesis Substrate, N-Pr-4-S-CAP as a Potential Source for Selective Chemoimmunotherapy of Malignant Melanoma
20. Binary outcomes of enhancer activity underlie stable random monoallelic expression

图：Syd Labs PA007167.r2b 体内实验级重组抗小鼠CD8a单克隆抗体（克隆号2.43）文献应用

二、 Syd Labs 重组抗小鼠 CD8a 单抗（克隆号 2.43）产品特性

Syd Labs 体内实验级重组抗小鼠 CD8a 单克隆抗体（货号：PA007167.r2b）专为体内细胞耗竭实验（In Vivo CD8+ T Cell Depletion）优化设计：

• 重组表达工艺：使用哺乳动物表达系统重组合成，结合大鼠 IgG2b 恒定区与 2.43 杂交瘤特异性可变区，有效规避传统动物腹水生产带来的杂质与变异。
• 体内级高标准：内毒素控制在极低水平，无防腐剂及甘油添加，确保在频繁给药或高剂量注射时不引发小鼠非特异性炎症反应。
• 广泛的实验用途：可用于小鼠肿瘤模型中 CD8+ T 细胞的体内清除、流式细胞术（FACS）、免疫沉淀及免疫组织化学（IHC）检测。

三、 产品规格与技术服务支持

关于 Syd Labs 重组抗体的技术咨询、试剂选择、申请 Syd Labs 中国代理商 授权或真伪核验，欢迎随时联系官方服务团队：

• 服务平台：武汉多找找科技有限公司（www.duozhaozhao.com）
• 企业微信：duozhaozhao2024

特别声明：本文涉及的所有抗体与试剂仅限于科研使用，不得用于人类或动物的临床诊断或治疗。